Keli Simpson
Primary Care · Punxsutawney, PANPI 1639692148
Payments from drug & device makers
Across 68 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$266
- Lilly USA, LLC$176
- AbbVie$122
- Abbott$82
- Exact Sciences$62
- Pfizer$53
- plus $370 from 15 others
What the payments were for
- Food & beverage$1,131100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $266 |
| Lilly USA, LLC | 10 | $176 |
| AbbVie | 6 | $122 |
| Abbott | 4 | $82 |
| Exact Sciences | 3 | $62 |
| Pfizer | 3 | $53 |
| GSK | 3 | $51 |
| Dexcom, Inc. | 3 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| AstraZeneca | 2 | $35 |
| Irhythm Technologies, Inc. | 2 | $33 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $20 |
| Amgen | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Shield Therapeutics Inc | 1 | $18 |
| Boston Scientific | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Exeltis, USA Inc. | 1 | $13 |
| Merck | 1 | $13 |
How this compares
$1,131 in reported general payments places this provider in the 65th percentile of 300 primary care providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 90 | $82,562 |
| MounjaroTirzepatide | 43 | $44,401 |
| EliquisApixaban | 48 | $36,367 |
| JardianceEmpagliflozin | 28 | $26,501 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $22,554 |
| TrulicityDulaglutide | 14 | $20,139 |
| FarxigaDapagliflozin Propanediol | 24 | $18,542 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,684 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $6,443 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $5,606 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 67 | $2,058 |
| Levemir FlexpenInsulin Detemir | 12 | $1,911 |
| Atorvastatin Calcium | 126 | $1,859 |
| Omeprazole | 133 | $1,834 |
| Duloxetine Hcl | 75 | $1,728 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $266 | $82,56290 claims |
| Lilly USA, LLCMounjaro, Trulicity | $176 | $64,54057 claims |
| PfizerEliquis | $53 | $36,36748 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $51 | $29,23751 claims |
| Boehringer IngelheimJardiance | $14 | $26,50128 claims |
| AstraZenecaFarxiga | $35 | $18,54224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 300 primary care providers in Pennsylvania.
Other primary care in Punxsutawney
- Kersten ReiderMount Penn$121K
- Teresa GiamboyPhiladelphia$21K
- Nicole IlgenfritzBethel Park$18K
- Galyna VorokhibPhiladelphia$12K
- Melissa BeansWarrington$12K
- Mollie McGuireJohnstown$11K
- Andrea MauriceNew Cumberland$11K
- Kendell SoglieroSmithfield$9K
- Minjung RegerDoylestown$9K
- Mackenzie HouserMedia$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.